Can exocrine pancreatic insufficiency impair vitamin B12 absorption?

Exocrine pancreatic insufficiency (EPI) is a recognized cause of vitamin B12 malabsorption due to the critical role pancreatic enzymes play in the biochemistry of cobalamin transport. While B12 is most often associated with gastric intrinsic factor, its successful absorption depends on a multi-step "hand-off" between different binding proteins that requires a functional exocrine pancreas.

Mechanistic basis of malabsorption

The absorption of vitamin B12 involves a sequential binding process that begins in the mouth and stomach and concludes in the small intestine:

• Haptocorrin binding: In the stomach, dietary B12 binds to haptocorrin (also known as R-binder), a glycoprotein found in saliva and gastric juice. This complex protects the vitamin from the highly acidic environment of the stomach.
• Proteolytic release: When the B12-haptocorrin complex enters the duodenum, it encounters pancreatic proteases, specifically trypsin and chymotrypsin. These enzymes degrade the haptocorrin, releasing the B12.
• Intrinsic factor transition: Intrinsic factor (IF), produced by the stomach, is present in the duodenum but cannot bind B12 while the vitamin is still attached to haptocorrin. Once pancreatic proteases degrade the haptocorrin, the B12 is free to bind with IF.
• Ileal absorption: The resulting B12-IF complex travels to the terminal ileum, where it is recognized by specific receptors (cubam) for absorption into the bloodstream.

Clinical evidence in pancreatic insufficiency

In individuals with EPI, the lack of sufficient pancreatic proteases interrupts this transition:

• Sequestration: Without adequate trypsin and chymotrypsin, haptocorrin remains intact, keeping the B12 sequestered. Because the B12-haptocorrin complex cannot be absorbed by the ileum, the vitamin remains in the intestinal lumen and is eventually excreted.
• Correction with enzymes: Clinical studies have demonstrated that B12 malabsorption in patients with pancreatic disease can be corrected through the administration of pancreatic enzyme replacement therapy (PERT) or purified trypsin. These interventions restore the proteolytic environment necessary to degrade R-binders and allow B12 to bind to intrinsic factor.
• Prevalence: While secondary B12 deficiency is less common than fat-soluble vitamin deficiencies (A, D, E, and K) in EPI, it remains a documented clinical risk, particularly in chronic or severe cases of pancreatic insufficiency.

Bottom line

The claim is fully supported. Pancreatic proteases are biochemically essential for releasing vitamin B12 from haptocorrin (R-binder) in the small intestine. Without these enzymes, B12 cannot bind to intrinsic factor, leading to malabsorption even if dietary intake and gastric function are normal.